Evidence map›Paper›PMID 31835359›Full record

ArticleMolecules (Basel, Switzerland)2019

Novel Homo-Bivalent and Polyvalent Compounds Based on Ligustrazine and Heterocyclic Ring as Anticancer Agents.

Jiawen Wang, Ge Hong, Guoliang Li, Wenzhi Wang, Tianjun Liu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jiawen WangGraduate Institute, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Ge HongTianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.
Guoliang LiTianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.
Wenzhi WangTianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.
Tianjun LiuGraduate Institute, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNTianjin University of Traditional Chinese Medicine · CN

Funding

the medical and health science and technology innovation project of Chinese Academy of Medical Science 2017-I2M-3-021/2019-I2M-1-005the national major science and technology special project for "significant new drugs development" 2018ZX09711001-005-018the Tianjin special support program for talent development TJTZJH-GCCCXCYTD-1-30
6 · The paper itself

Abstract

Bivalent and polyvalent inhibitors can be used as antitumor agents. In this experiment, eight ligustrazine dimers and seven ligustrazine tetramers linked by alkane diamine with different lengths of carbon chain lengths were synthesized. After screening their antiproliferation activities against five cancer cell lines, most ligustrazine derivatives showed better cytotoxicity than the ligustrazine monomer. In particular, ligustrazine dimer

Indexed as

Antineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationChromatography, High Pressure LiquidFluorescent Antibody TechniqueHeterocyclic CompoundsHumansMembrane Potential, MitochondrialPyrazinesStructure-Activity RelationshipAntineoplastic AgentsHeterocyclic CompoundsPyrazinestetramethylpyrazineantitumorapoptosisbivalencycell cyclepolyvalency

Identifiers

PMID31835359
PMCPMC6943434
OpenAlexW2993103000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.